Price
No data yet.
Social Signal Score
Analyst Ratings
4 analystsRevenue
$48.86M+94.72%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Mark Steven Fogel
- Sector
- Real Estate
- Industry
- REIT - Mortgage
- Employees
- 4
- Beta
- 1.10
- Country
- US
- Piotroski score
- 5 / 9 (Middling)
- Altman Z-score
- -0.21
Financials
Revenue
$48.86M+94.7%Net Income
$-7.42MEBITDA
$25.65MFree Cash Flow
$5.47MEPS (diluted)
$-1.87Shares Outstanding (diluted)
6.69M-34.2%Operating Expenses
$2.72MCash & Debt
$41.95MReturn of Capital
$5.12MRevenue by Segment (annual)
$125.36MDividend per Share
$0.82Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $165.90M | $21.32M | $0.03 |
| 2024 | $83.49M | $29.27M | $1.19 |
| 2023 | $91.13M | $22.39M | $0.35 |
| 2022 | $62.88M | $10.62M | $-1.00 |
| 2021 | $106.43M | $33.92M | $1.85 |
| 2020 | $-80.86M | $-197.71M | $-19.33 |
| 2019 | $56.47M | $35.97M | $2.46 |
| 2018 | $36.62M | $27.43M | $0.66 |
| 2017 | $45.96M | $33.54M | $0.54 |
| 2016 | $62.68M | $-30.36M | $-5.19 |
| 2015 | $123.92M | $10.55M | $0.98 |
| 2014 | $112.30M | $61.20M | $4.08 |
| 2013 | $91.59M | $46.45M | $3.96 |
| 2012 | $107.72M | $64.44M | $8.52 |
Valuation
Project earnings forward and see what return today's price implies.
Seeded from ACR's reported EPS growth of -34.7% a year over 13 years. Historical EPS growth of -35% would project the company towards zero. Floored at -15% as a starting point.
- EPS in 5 years
- $1.33
- Implied price
- $23.88
- Return from $11.69
- 15.4% a year
To earn 15.0% a year on these assumptions you'd need to buy at $11.87 — today's price is already 1.5% below that.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 12 | 15 | 18 | 21 | 24 |
|---|---|---|---|---|---|
| -25.0% | -6.1% | -1.9% | 1.8% | 5.0% | 7.8% |
| -20.0% | 0.1% | 4.7% | 8.6% | 12.0% | 15.0% |
| -15.0% | 6.4% | 11.2% | 15.4% | 19.0% | 22.2% |
| -10.0% | 12.6% | 17.8% | 22.1% | 26.0% | 29.4% |
| -5.0% | 18.9% | 24.3% | 28.9% | 33.0% | 36.6% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
50+66.67%Social Signal Score
Mentions (9)
- Newsprnewswire.com·3d ago·Neutral
ACRES Commercial Realty Corp. to Report Results for Third Quarter 2026 UNIONDALE, N.Y., Oct. 21, 2026 /PRNewswire/ -- ACRES Commercial Realty Corp. (NYSE: ACR) (the "Company" or "ACRES") announced today that it will release its results for the third quarter 2026 on Wednesday, November 4, 2026, after the market closes.
View source ↗ - Newsglobenewswire.com·4d ago·Negative
Acrivon Advances ACR-7280, an Optimized, AP3-Enabled, Potential First-in-Class, Oral CDK11 Inhibitor Toward IND Filing in First Half of 2027 ACR-7280 demonstrated complete tumor regression in aggressive AML xenograft models Prioritized among multiple AP3-discovered, highly selective CDK11 inhibitor candidates based on potent single agent activity and strong synergy with BCL-2 and menin inhibitors IND-enabling studies ongoing with IND submission on track for first half of 2027 WATERTOWN, Mass., O…
View source ↗ - Newsglobenewswire.com·22d ago·Neutral
CRISPR Therapeutics to Present Clinical Data on Zugocabtagene Geleucel (Zugo-cel) in Autoimmune Disease at the American College of Rheumatology (ACR) Convergence 2026 ZUG, Switzerland and BOSTON, Oct. 02, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), today announced that a poster presentation highlighting the Company's Phase 1 clinical data of its investigational CRISPR/Cas9 gene-edited allogeneic CAR T cell therapy, zugocabtagene geleucel (zugo-cel) targeting CD19 for autoimmune …
View source ↗ - Newsglobenewswire.com·22d ago·Negative
Artiva Biotherapeutics Announces Multiple AlloNK® Data Presentations at the American College of Rheumatology (ACR) Convergence 2026 Oral presentation highlighting updated clinical data from at least 20 patients with refractory rheumatoid arthritis (RA), 11 patients with Sjögren disease (SjD) and at least five patients with systemic sclerosis (SSc) treated with AlloNK plus rituximab in the ongoing Phase 2a basket trial, all with at least six months of follow-up Poster presentation highlighting de…
View source ↗ - Newszacks.com·23d ago·Neutral
ACRES Commercial (ACR) Moves 9.5% Higher: Will This Strength Last? ACRES Commercial (ACR) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
View source ↗ - Newsprnewswire.com·25d ago·Neutral
ACRES Commercial Realty Corp. Reauthorizes an Additional $5 Million Share Repurchase Program UNIONDALE, N.Y., Sept. 29, 2026 /PRNewswire/ -- ACRES Commercial Realty Corp. (NYSE:ACR) (the "Company") announced today that its board of directors (the "Board") authorized and approved the continued use of its existing share repurchase program to repurchase an additional $5.0 million of the outstanding shares of its common stock.
View source ↗ - Newsglobenewswire.com·32d ago·Positive
Zenas BioPharma Announces Upcoming Presentations of Obexelimab Data in IgG4-Related Disease at the IgG4ward! 6th International Symposium on IgG4-Related Disease and ACR Convergence 2026 – New data from the Phase 3 INDIGO open-label extension will include the longer-term flare protection and safety data of obexelimab in IgG4-RD –
View source ↗ - Newsprnewswire.com·38d ago·Negative
ACRES Commercial Realty Corp. Declares Quarterly Cash Dividends for its Preferred Stock UNIONDALE, N.Y., Sept. 16, 2026 /PRNewswire/ -- ACRES Commercial Realty Corp. (NYSE: ACR) (the "Company") announced today that its Board of Directors declared cash dividends on its Preferred Stock.
View source ↗ - Newsglobenewswire.com·46d ago·Negative
Nkarta to Present Initial Autoimmune Clinical Data for NKX019 at American College of Rheumatology (ACR) Convergence 2026 SOUTH SAN FRANCISCO, Calif., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biotechnology company developing engineered natural killer (NK) cell therapies to treat autoimmune diseases, today announced its selection for three scientific presentations at ACR Convergence 2026 being held November 6-11 in Orlando.
View source ↗
Earnings
Wed, Nov 4(in 10 days)
Consensus estimate $0.15 per share
Typical surprise -55.6% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Jul 29$-0.74 vs $0.18miss
- Thu, Apr 30$0.02 vs $0.04miss
- Wed, Mar 4$-0.48 vs $0.14miss
- Wed, Oct 29$1.01 vs $0.14beat
- Wed, Jul 30$0.04 vs $0.01beat
- Wed, Apr 30$-0.86 vs $0.53miss
Estimates and results for ACR via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by ACR officers and directors.
- Bought
- —
- Sold
- $2.6m
0 trades
73 trades
- Bryant David Jsold
- Eagle Point Credit Management Llcsold
- Eagle Point Credit Management Llcsold
- Eagle Point Credit Management Llcsold
- Eagle Point Credit Management Llcsold
- Eagle Point Credit Management Llcsold
- Eagle Point Credit Management Llcsold
- Eagle Point Credit Management Llcsold
27 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in ACR.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.